Search results
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.
The team have found the cause of disease in the first ever family tree drawn up at Moorfields Eye Hospital over 35 years ago, which had remained unsolved until now.
Hajrah Sarkar is a PhD student whose project is funded by Retina UK.
Nurturing a new generation of scientists is a vital investment in the future of retinal disease research, so we are delighted to be funding, in collaboration with the Macular Society, a new PhD studentship at Oxford University, supervised by Professor Robert MacLaren.
Inherited progressive sight loss is caused by a range of rare genetic conditions. We specialise in those which affect the retina.
The BBC covered a story on Monday 24 May about optogenetics partially restoring the sight of a man living with retinitis pigmentosa in France.
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Celebrate the life of your loved one, by donating in their memory and help us fund more research and support, now.
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
Thursday 19 September, 11.00am - 1.00pm - In-person - Come and join us at the Princess Alexandra Eye Pavilion for a special focus group with Dr. Roly Megaw.
